X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3087) 3087
Publication (248) 248
Newsletter (60) 60
Newspaper Article (42) 42
Book Review (40) 40
Book Chapter (33) 33
Dissertation (9) 9
Magazine Article (5) 5
Transcript (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Presentation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2126) 2126
index medicus (1180) 1180
hematology (1120) 1120
animals (907) 907
thrombin (676) 676
peripheral vascular disease (653) 653
male (578) 578
biochemistry & molecular biology (509) 509
female (503) 503
coagulation (464) 464
blood coagulation factors (457) 457
anticoagulants (452) 452
blood-coagulation (421) 421
tissue factor (408) 408
thrombosis (389) 389
blood coagulation (386) 386
coagulation factors (381) 381
kinetics (325) 325
blood coagulation - drug effects (299) 299
factor xa (298) 298
factor xa - metabolism (298) 298
adult (297) 297
factor xa inhibitors (296) 296
prothrombin (285) 285
middle aged (282) 282
blood coagulation factors - metabolism (279) 279
hemophilia (279) 279
activation (270) 270
analysis (266) 266
factor-xa (266) 266
protein binding (264) 264
proteins (263) 263
blood (252) 252
amino acid sequence (245) 245
thrombin - metabolism (244) 244
plasma (236) 236
binding sites (231) 231
research (231) 231
models, molecular (230) 230
thromboplastin - metabolism (230) 230
blood coagulation factor viii (228) 228
hemostasis (225) 225
anticoagulants - pharmacology (219) 219
molecular sequence data (215) 215
aged (214) 214
activated protein-c (213) 213
mice (201) 201
mutation (200) 200
coagulation factor xa (178) 178
pharmacology & pharmacy (175) 175
binding (174) 174
blood coagulation tests (173) 173
heparin (168) 168
coagulation factor-xa (166) 166
thrombin generation (164) 164
fibrin (162) 162
anticoagulants - therapeutic use (160) 160
rivaroxaban (159) 159
factor x - metabolism (158) 158
structure-activity relationship (155) 155
blood coagulation - physiology (153) 153
anticoagulant (152) 152
factor viii (150) 150
blood coagulation factors - therapeutic use (149) 149
coagulation-factor-v (149) 149
factor xa - chemistry (146) 146
risk factors (146) 146
coagulation-factor xa (143) 143
partial thromboplastin time (143) 143
protein c (143) 143
protein conformation (143) 143
article (138) 138
factor-ix (138) 138
thromboembolism (138) 138
prothrombin - metabolism (136) 136
venous thromboembolism (134) 134
chemistry, medicinal (133) 133
health aspects (133) 133
expression (131) 131
dose-response relationship, drug (128) 128
venous thrombosis (128) 128
blood coagulation factors - physiology (127) 127
prothrombin complex concentrate (127) 127
factor pathway inhibitor (125) 125
inhibitors (123) 123
recombinant proteins - metabolism (123) 123
factor v (122) 122
warfarin (122) 122
platelets (121) 121
blood coagulation factors - analysis (120) 120
cattle (120) 120
multidisciplinary sciences (120) 120
time factors (120) 120
prothrombin time (119) 119
bleeding (118) 118
protein c - metabolism (118) 118
von-willebrand-factor (117) 117
factor-viii (116) 116
medical examination (115) 115
crystal-structure (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3184) 3184
Japanese (35) 35
German (10) 10
Chinese (6) 6
French (6) 6
Russian (6) 6
Polish (3) 3
Spanish (3) 3
Italian (2) 2
Danish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 05/2017, Volume 15, Issue 5, pp. 931 - 937
Essentials FXaI16L is a recombinant zymogen‐like variant of activated coagulation factor X (FXa). A phase 1 dose escalation clinical trial of FXaI16L was... 
clinical trial | hematologic agents | hemorrhagic disorders | blood coagulation factor | activated partial thromboplastin time | PF‐05230907 | PF-05230907 | HUMAN-PLASMA | ACTIVATION | PROTEIN | BYPASS | FACTOR-VIII | SPONTANEOUS INTRACEREBRAL HEMORRHAGE | THROMBIN GENERATION | INHIBITION | HEMOPHILIA-A | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Factor Xa - administration & dosage | Injections, Intravenous | Area Under Curve | Fibrin Fibrinogen Degradation Products - metabolism | Humans | Prothrombin Time | Half-Life | Male | Metabolic Clearance Rate | Recombinant Proteins | Healthy Volunteers | Young Adult | Peptide Hydrolases - blood | Antithrombin III | Coagulants - administration & dosage | Peptide Fragments - blood | Adult | Coagulants - pharmacokinetics | Factor Xa - adverse effects | Factor Xa - immunology | Double-Blind Method | Factor Xa - pharmacokinetics | Biomarkers - blood | Blood Coagulation - drug effects | Partial Thromboplastin Time | Adolescent | Prothrombin | Antibodies - blood | Coagulants - adverse effects | Coagulants - immunology | Coagulation factor X | Pharmacodynamics | Intravenous administration | Toxicity | Coagulation | Clinical trials | Thrombin | Antithrombin | Hemorrhage | Bleeding | Antibody response | Proenzymes | Thromboplastin | Coagulation factors | Immunogenicity | Plasma levels | Pharmacokinetics
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2007, Volume 50, Issue 22, pp. 5339 - 5356
Journal Article
Nature Medicine, ISSN 1078-8956, 04/2013, Volume 19, Issue 4, pp. 446 - 451
Journal Article
JOURNAL OF BIOLOGICAL CHEMISTRY, ISSN 0021-9258, 10/2019, Volume 294, Issue 41, pp. 15176 - 15181
Skeletal muscle myosin has potent procoagulant activity that is based on its ability to enhance thrombin generation due to binding coagulation factors Xa and... 
thrombin | SKELETAL-MUSCLE MYOSIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | myosin | peptides | CONFORMATION | APIXABAN | HEAVY-CHAIN | WARFARIN | coagulation factor | factor Xa | skeletal muscle | BINDING | SUBFRAGMENT-1
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 03/2008, Volume 130, Issue 9, pp. 2817 - 2831
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2019, Volume 17, Issue 1, pp. 126 - 137
Summary Essentials Emicizumab mimics factor (F)VIIIa cofactor function, augments the intrinsic tenase activity. We assessed the emicizumab‐driven hemostatic... 
emicizumab | thrombin generation assay | plasma | clot waveform analysis | factor XI deficiency | ACTIVATION | MECHANISM | MODEL | HEMOPHILIA-A PATIENTS | FACTOR-IX | PERIPHERAL VASCULAR DISEASE | INHIBITORS | HEMATOLOGY | Plasma | Blood coagulation | Phenotypes | Propagation | Calcium | Tissue factor | Thrombin | Phospholipids | Thromboplastin | Coagulation factors | Ellagic acid | Monoclonal antibodies | Bispecific antibodies
Journal Article
Circulation, ISSN 0009-7322, 05/2007, Volume 115, Issue 20, pp. 2642 - 2651
Journal Article